Analyst Price Target is $7.50
▲ +54.96% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for DBV Technologies in the last 3 months. The average price target is $7.50, with a high forecast of $8.00 and a low forecast of $7.00. The average price target represents a 54.96% upside from the last price of $4.84.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in DBV Technologies. This rating has held steady since December 2019, when it changed from a Hold consensus rating.
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.